Removal of crystal violet from aqueous solution using desert date (Balanites aegyptiaca) seed shell

The feasibility of utilizing desert date seed shell (DDSS) as an alternative low-cost adsorbent for the removal of hazardous crystal violet (CV) dye from aqueous solution was investigated. The prepared adsorbent was characterized by Fourier transform infrared (FTIR) spectroscopy (Cary 630; Agilent Technologies) and scanning electron microscopy (PRO: X: Phenonm World 800-07334). The influence of operational parameters such as contact time, adsorbent dosage, pH, and temperature were studied using batch mode technique. The obtained results showed that 60 min contact time, 0.4g adsorbent dose, solution pH of 8 and 60 oC temperature resulted in maximum CV removal. The equilibrium data fitted very well to Freundlich model (R 2 = 0.9983) and the KF and 1/n values were found to be 31.21 dm3g -1 and 0.828 respectively. The maximum adsorption capacity of DDSS for CV as determined by Langmuir isotherm is 294.12 mg g -1at 303K. Kinetic analysis revealed that the pseudo second order was the best model (R 2 = 0.9999) for the description of CV uptake with the experimental value of qe 20.3575 mg g -1 being closer to the calculated value of the qe 20.3651 mg g -1 . Thermodynamic studies revealed a negative value for ∆G o (-11.07 kJ mol -1 ) and a positive value for ∆H o (33.75 kJ mol -1 ) and ∆S o (134.9 J mol -1 K-1  ). These indicated the  spontaneous and endothermic nature of the adsorption process. Keywords: Adsorption, Desert date seed shell, Crystal violet, Batch  mode, Modelin

Reclamation of malachite green-bearing wastewater using desert date seed shell: adsorption isotherms, desorption and reusability studies

A low-cost activated carbon adsorbent was prepared from desert date seed shell (DDSS) and utilized for the removal of hazardous malachite green (MG) from aqueous solution using batch mode technique. Different isotherm models were applied to acquire the theoretical data of MG adsorption onto the adsobent at variable initial concentration of 100-1000 mg dm-3. Based on the coefficient of determination (R2), isotherm models exhibit the following sequence: Freundlich > Langmuir > Redlich-Peterson > Temkin > Jovanovic > Harkin- Jura > Elovich > Dubinin-Radushkevic. The maximum monolayer capacity of the adsorbent was found to be 312.5 mg g-1 at 303 K. The mean free energy value (0.91 kJ mol-1) obtained from D-R isotherm suggests that the adsorption process follows physisorption mechanism. Desorption studies for reusability revealed that acetic acid offered the best recovery (52.09%) and the process follow pseudo-second-order kinetics. The conducted reusability test revealed the decline of the adsorbent performance from 96.5% MG removal down to 70.5% MG removal after 5 successive adsorption/desorption cycles.Keywords: Activated Carbon, Desorption, Isotherms, Malachite Green, Reusabilit

Balancing Demand, Quality and Efficiency in Nigerian Health Care Delivery System

The health sector is crucial to growth and development of a nation. Despite sound policies and interventions to develop the Nigerian health sector, it has witnessed several challenges that continue to reduce the progress and achievement of universal access to health care. Some of the factors that affect the overall performance of the health system include; inadequate health facilities/structure, poor human resources and management, poor remuneration and motivation, lack of fair and sustainable health care financing, unequal economic and political relations, the neo-liberal economic policies of the Nigerian state, corruption, illiteracy, very low government spending on health, high out-of-pocket expenditure in health and absence of integrated system for disease prevention, surveillance and treatment, inadequate mechanisms for families to access health care, shortage of essential drugs and supplies and inadequate supervision of health care providers are among some of the persistent problems of the health system in Nigeria. This paper looks at the enormity of the problems and recommends policy options vital to addressing the problems in order to attain the equilibrium in demand, quality and efficiency in the health care delivery system in Nigeria. Keywords: Demand, Quality, efficiency, health care system, Nigeri

Sports/energy drinks consumption among young athletes in Kano, Nigeria

Little is known about the prevalence and motives of sport drinks use among adolescents and young adult athletes who exercise on regular basis in most football and other games pitches. Therefore, the current study was performed to assess information regarding the use of sport drinks among 440 athletes (23.5±4.62 years of age) in Kano Nigeria. Data were collected using a selfadministered, structured and pretested  questionnaire. The results indicated that the frequency of sport drinks  consumption was higher among male athletes and in those who did not have breakfast on a regular basis, ever smoked cigarettes and drank alcoholic beverages compared with their female counterparts. Athletes who had ‘ever’ tried a sport drink were significantly higher (p<0.05) than those who had ‘never’ tasted the drink. Main reasons for using such drinks for regular users varied across the selected groups of athletes and included obtaining energy and boosting performance while doing sport. Most athletes claimed to be aware of the ingredients of sport drinks or their potential hazardous health effects, and that they could distinguish between sport and energy drinks. This study discovered that energy drinks were consumed by the athletes rather than sport drinks and that sport drinks are still alien to the study community as they are not commonly available in the market. This stands in strong contrast to the assumption that  athletes consumed sport drinks. Therefore, increased awareness among the athletes of the discrepancies, ingredients and potential health hazards of both sport and energy drinks should be sustained.Keywords: Sport drinks, consumption, adolescents, young adults, athlete

Breast Imaging Reporting and Data Systems category 3 (probably benign) breast lesions detected on diagnostic breast ultrasound: The prevalence, outcome and malignancy detection rate in Zaria, Nigeria

Background: Probably benign breast lesions in the Breast Imaging Reporting and Data Systems (BI-RADS 3) constitute a crucial category and a considerable number of all palpable breast masses. Local data concerning the outcome of such lesions in the Nigerian environment is almost non-existent. Objectives: The goal of this article is to report the frequency, outcome and malignancy detection rate among palpable breast masses that were categorised on ultrasound as BI-RADS category 3 (probably benign) according to the American College of Radiology (ACR). Methods: Between January 2015 and July 2017, 603 patients had diagnostic whole-breast ultrasound scans. There were 277 women who complained of palpable breast masses, of whom 151 women were diagnosed as having BI-RADS 3 lesions. The final lesion outcome was determined by either biopsy or ultrasound follow-up examination for a total of 2 years. All data were recorded and analysed with Statistical Package for the Social Sciences (SPSS) version 20 (Chicago, USA). Results: The frequency of BI-RADS category 3 lesions among all the women who underwent breast ultrasound was 25% (151/603); and 54% (151/277) in patients with palpable breast masses. There were 25 patients who were excluded because of incomplete data or who were lost to follow-up. A total of 122 patients had both ultrasound examination and histopathologic diagnosis, while only 4 were followed up for 2 years on ultrasound alone. Of the 122 women biopsied, 117 (95.9%) had benign histologic outcomes, and of the remaining 5, cancer was confirmed in 2 (1.6%), while the remaining 3 patients (2.5%) had lesions considered intermediate at histology (juvenile papillomatosis, borderline phylloides and atypical ductal hyperplasia). Three out of four patients who had ultrasound follow-up alone had stable lesions after 2 years, while one patient had complete resolution. Conclusion: This study found a significantly high biopsy rate of 80% (122/151) for probably benign lesions but a low detection rate for malignancy (1.6%). Follow-up with imaging rather than biopsy for lesions sonographically described as probably benign, will reduce medical costs and unwarranted invasive procedures

Hearing Loss Prevalence and Years Lived With Disability, 1990–2019: Findings From the Global Burden of Disease Study 2019

Background Hearing loss affects access to spoken language, which can affect cognition and development, and can negatively affect social wellbeing. We present updated estimates from the Global Burden of Disease (GBD) study on the prevalence of hearing loss in 2019, as well as the condition\u27s associated disability. Methods We did systematic reviews of population-representative surveys on hearing loss prevalence from 1990 to 2019. We fitted nested meta-regression models for severity-specific prevalence, accounting for hearing aid coverage, cause, and the presence of tinnitus. We also forecasted the prevalence of hearing loss until 2050. Findings An estimated 1.57 billion (95% uncertainty interval 1.51-1.64) people globally had hearing loss in 2019, accounting for one in five people (20.3% [19.5-21.1]). Of these, 403.3 million (357.3-449.5) people had hearing loss that was moderate or higher in severity after adjusting for hearing aid use, and 430.4 million (381.7-479.6) without adjustment. The largest number of people with moderate-to-complete hearing loss resided in the Western Pacific region (127.1 million people [112.3-142.6]). Of all people with a hearing impairment, 62.1% (60.2-63.9) were older than 50 years. The Healthcare Access and Quality (HAQ) Index explained 65.8% of the variation in national age-standardised rates of years lived with disability, because countries with a low HAQ Index had higher rates of years lived with disability. By 2050, a projected 2.45 billion (2.35-2.56) people will have hearing loss, a 56.1% (47.3-65.2) increase from 2019, despite stable age-standardised prevalence. Interpretation As populations age, the number of people with hearing loss will increase. Interventions such as childhood screening, hearing aids, effective management of otitis media and meningitis, and cochlear implants have the potential to ameliorate this burden. Because the burden of moderate-to-complete hearing loss is concentrated in countries with low health-care quality and access, stronger health-care provision mechanisms are needed to reduce the burden of unaddressed hearing loss in these settings

Pharmacognostic and Acute Toxicity Study of Burkea Africana Root

Burkea africana is a plant that belongs to then family Fabaceae; it is widely spread in tropical Africa including Nigeria. It is of valuable in  ethnomedicine especially in the treatment of antidote for venomous stings and bites, cutaneous and sub cutaneous parasitic infection, convulsion and pulmonary troubles. Despite the fact that roots of Burkea africana have several medicinal properties, no standardization parameter has been  assessed. Due to lack of standard parameters, proper identification and ascertaining quality and purity in the events of adulteration has been thwarted. The objective of the study was to establish some important pharmacognostic profile and safety margin of Burkea africana root with the hope of assisting in its standardization for quality, purity and safety. Elemental analysis was carried out using acid digestion method and phytochemical composition of the plants was evaluated using standard method. Acute toxicity was achieved using Lorke method to determine the LD50. Chemomicroscopical evaluation revealed the presence of cellulose, tannins, starch, lignin, calcium oxalate, suberin, aleurone grain and mucilage with the exception of calcium carbonate. The average moisture contents, total ash, acid insoluble, water soluble ash, alcohol extractive value and water extractive values in the powdered plant material were 3.8%, 7.5%, 4.43%, 8.07%, 25.0% and 20.33% respectively. In addition, Fe, Mn, Ni, Pb, Cd and Cu were found to be within the safety limit. Phytochemicals which include alkaloids, flavonoids, saponins, tannins, carbohydrates and triterpenes were detected in both aqueous and methanolic extracts. The LD50 of Burkea africana was found to be greater than 5000 mg /kg and could be considered safe for consumption. Keywords: Elemental analysis, Burkea africana, Pharmacognostic, Phytochemica

Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021

BACKGROUND: Previous global analyses, with known underdiagnosis and single cause per death attribution systems, provide only a small insight into the suspected high population health effect of sickle cell disease. Completed as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, this study delivers a comprehensive global assessment of prevalence of sickle cell disease and mortality burden by age and sex for 204 countries and territories from 2000 to 2021. METHODS: We estimated cause-specific sickle cell disease mortality using standardised GBD approaches, in which each death is assigned to a single underlying cause, to estimate mortality rates from the International Classification of Diseases (ICD)-coded vital registration, surveillance, and verbal autopsy data. In parallel, our goal was to estimate a more accurate account of sickle cell disease health burden using four types of epidemiological data on sickle cell disease: birth incidence, age-specific prevalence, with-condition mortality (total deaths), and excess mortality (excess deaths). Systematic reviews, supplemented with ICD-coded hospital discharge and insurance claims data, informed this modelling approach. We employed DisMod-MR 2.1 to triangulate between these measures-borrowing strength from predictive covariates and across age, time, and geography-and generated internally consistent estimates of incidence, prevalence, and mortality for three distinct genotypes of sickle cell disease: homozygous sickle cell disease and severe sickle cell β-thalassaemia, sickle-haemoglobin C disease, and mild sickle cell β-thalassaemia. Summing the three models yielded final estimates of incidence at birth, prevalence by age and sex, and total sickle cell disease mortality, the latter of which was compared directly against cause-specific mortality estimates to evaluate differences in mortality burden assessment and implications for the Sustainable Development Goals (SDGs). FINDINGS: Between 2000 and 2021, national incidence rates of sickle cell disease were relatively stable, but total births of babies with sickle cell disease increased globally by 13·7% (95% uncertainty interval 11·1-16·5), to 515 000 (425 000-614 000), primarily due to population growth in the Caribbean and western and central sub-Saharan Africa. The number of people living with sickle cell disease globally increased by 41·4% (38·3-44·9), from 5·46 million (4·62-6·45) in 2000 to 7·74 million (6·51-9·2) in 2021. We estimated 34 400 (25 000-45 200) cause-specific all-age deaths globally in 2021, but total sickle cell disease mortality burden was nearly 11-times higher at 376 000 (303 000-467 000). In children younger than 5 years, there were 81 100 (58 800-108 000) deaths, ranking total sickle cell disease mortality as 12th (compared to 40th for cause-specific sickle cell disease mortality) across all causes estimated by the GBD in 2021. INTERPRETATION: Our findings show a strikingly high contribution of sickle cell disease to all-cause mortality that is not apparent when each death is assigned to only a single cause. Sickle cell disease mortality burden is highest in children, especially in countries with the greatest under-5 mortality rates. Without comprehensive strategies to address morbidity and mortality associated with sickle cell disease, attainment of SDG 3.1, 3.2, and 3.4 is uncertain. Widespread data gaps and correspondingly high uncertainty in the estimates highlight the urgent need for routine and sustained surveillance efforts, further research to assess the contribution of conditions associated with sickle cell disease, and widespread deployment of evidence-based prevention and treatment for those with sickle cell disease. FUNDING: Bill & Melinda Gates Foundation

Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019

Background Hearing loss affects access to spoken language, which can affect cognition and development, and can negatively affect social wellbeing. We present updated estimates from the Global Burden of Disease (GBD) study on the prevalence of hearing loss in 2019, as well as the condition's associated disability. Methods We did systematic reviews of population-representative surveys on hearing loss prevalence from 1990 to 2019. We fitted nested meta-regression models for severity-specific prevalence, accounting for hearing aid coverage, cause, and the presence of tinnitus. We also forecasted the prevalence of hearing loss until 2050. Findings An estimated 1·57 billion (95% uncertainty interval 1·51–1·64) people globally had hearing loss in 2019, accounting for one in five people (20·3% [19·5–21·1]). Of these, 403·3 million (357·3–449·5) people had hearing loss that was moderate or higher in severity after adjusting for hearing aid use, and 430·4 million (381·7–479·6) without adjustment. The largest number of people with moderate-to-complete hearing loss resided in the Western Pacific region (127·1 million people [112·3–142·6]). Of all people with a hearing impairment, 62·1% (60·2–63·9) were older than 50 years. The Healthcare Access and Quality (HAQ) Index explained 65·8% of the variation in national age-standardised rates of years lived with disability, because countries with a low HAQ Index had higher rates of years lived with disability. By 2050, a projected 2·45 billion (2·35–2·56) people will have hearing loss, a 56·1% (47·3–65·2) increase from 2019, despite stable age-standardised prevalence. Interpretation As populations age, the number of people with hearing loss will increase. Interventions such as childhood screening, hearing aids, effective management of otitis media and meningitis, and cochlear implants have the potential to ameliorate this burden. Because the burden of moderate-to-complete hearing loss is concentrated in countries with low health-care quality and access, stronger health-care provision mechanisms are needed to reduce the burden of unaddressed hearing loss in these settings

Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. // Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. // Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019. // Interpretation: After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines